Alvotech (ALVO)
(Delayed Data from NSDQ)
$13.88 USD
+0.11 (0.80%)
Updated May 31, 2024 04:00 PM ET
After-Market: $13.85 -0.03 (-0.22%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALVO 13.88 +0.11(0.80%)
Will ALVO be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ALVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALVO
Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Lags Revenue Estimates
ALVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Misses Revenue Estimates
Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates
Alvotech (ALVO) Up on BLA Update for Two Biosimilar Candidates
Other News for ALVO
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
Alvotech price target raised by $2 at Barclays, here's why
Alvotech (ALVO) Receives a Buy from Northland Securities
Alvotech (ALVO) Q1 2024 Earnings Call Transcript
Alvotech 2024 Q1 - Results - Earnings Call Presentation